TABLE 2

Systemic blood pressure, LV hemodynamic, and hematocrit changes in Nx control and treatment groups

The statistical differences between groups was determined by two-way ANOVA followed by Sidak’s post hoc test.

Nx (n = 11)Nx + 4091 (n = 6)Hx (n = 9)Hx + 4091 (n = 11)SuHx (n = 7)SuHx + 4091 (n = 6)
b.wt. (g)23 ± 326 ± 524 ± 323 ± 325 ± 326 ± 2
HR (bpm)455 ± 71508 ± 71455 ± 36466 ± 34519 ± 19408 ± 52¶¶
mAP (mm Hg)87.7 ± 12.476.5 ± 4.0*88.3 ± 6.785.4 ± 4.882.2 ± 15.385.0 ± 4.0
LVSP (mm Hg)104.0 ± 11.295.5 ± 3.9104.8 ± 5.796.8 ± 3.9101.8 ± 21.297.9 ± 4.6
LVEDP (mm Hg)11.2 ± 2.86.2 ± 3.215.2 ± 3.210.7 ± 1.916.5 ± 9.97.9 ± 2.3
dP/dt max (mm Hg/s)5841 ± 8036385 ± 4625559 ± 4965567 ± 6686021 ± 11145510 ± 1302
−dP/dt min (mm Hg/s)5266 ± 10295890 ± 5704945 ± 7884753 ± 5534648 ± 10994504 ± 1302
Ht (%)46 ± 344 ± 260 ± 3***48 ± 6§§§59 ± 3***56 ± 4
  • HR, heart rate; Ht, hematocrit.

  • * P < 0.05; **P < 0.001; ***P < 0.0001, comparison with Nx; §P < 0.05; §§P < 0.01; §§§P < 0.001, comparison with Hx; P < 0.05; ¶¶P < 0.001; ¶¶¶P < 0.0001, comparison with SuHx.